40 results
8-K
EX-3.3
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
vote of a majority of the directors then in office.
SECTION 7. Absence or Disability. In the event of the absence or disability of any officer
8-K
EX-10.6
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
not include any termination that occurs solely as a result of Participant’s death or Disability. The determination as to whether a Participant’s status … .
(o) “Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code, provided that in the case of Awards other than
425
56ewkwxmcnf jpja
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.2
g57hskmzwh81vu
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
xuz9k
10 Nov 21
Regulation FD Disclosure
7:12am
S-8
EX-99.2
7xo o89q2
7 Jun 21
Registration of securities for employees
4:02pm
S-8
EX-99.1
1ngbfwdj1o 9d
7 Jun 21
Registration of securities for employees
4:02pm
8-K
EX-10.7
uzk4jkly
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-10.2
gb3lbuno
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-10.1
q15sf8jkfsmi5zh
15 Dec 20
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis
7:34am
425
EX-10.1
pw9qe
15 Dec 20
Business combination disclosure
7:32am